In our analysis, we demonstrated overexpression of UBA2 mRNA, and the protein coded by it in ovarian cancer samples (p < 0.05), it was higher in group A where surgical treatment was complemented by chemotherapy when compared with group B where treatment was terminated by surgery. This evidence concerns the gene UBA2 and ovarian carcinoma.